Journal Mobile Options
Table of Contents
Vol. 113, No. 1, 2009
Issue release date: March 2009
Cardiology 2009;113:12–19

Impact of Intravenous Loop Diuretics on Outcomes of Patients Hospitalized with Acute Decompensated Heart Failure: Insights from the ADHERE Registry

Peacock W.F. · Costanzo M.R. · De Marco T. · Lopatin M. · Wynne J. · Mills R.M. · Emerman C.L.
aDepartment of Emergency Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, bMidwest Heart Foundation, Lombard, Ill., cDivision of Cardiology, University of California, San Francisco, Calif., dScios Inc., Fremont, Calif., and eDepartment of Emergency Medicine, Case Western Reserve University, Cleveland, Ohio, USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


The optimal use of diuretics in decompensated heart failure remains uncertain. We analyzed data from the ADHERE registry to look at the impact of diuretic dosing. 62,866 patients receiving <160 mg and 19,674 patients ≥160 mg of furosemide were analyzed. The patients receiving the lower doses had a lower risk for in-hospital mortality, ICU stay, prolonged hospitalization, or adverse renal effects. These findings suggest that future studies should evaluate strategies for minimizing exposure to high doses of diuretics.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Heart Failure Society of America: Evaluation and management of patients with acute decompensated heart failure: Section 12 of HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail 2006;12:e86–e103.
  2. Domanski M, Norman J, Pitt B, et al: Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 2003;42:705–708.
  3. Domanski M, Tian X, Haigney M, Pitt B: Diuretic use, progressive heart failure, and death in patients in the DIG study. J Card Fail 2006;12:327–332.
  4. Butler J, Forman DE, Abraham WT, et al: Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 2004;147:331–338.
  5. Forman DE, Butler J, Wang Y, et al: Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 2004;43:61–67.
  6. Eshaghian S, Horwich TB, Fonarow GC: Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 2006;97:1759–1764.
  7. Adams KF, Fonarow GC, Emerman CL, et al: Characteristics and outcomes of patients hospitalized for heart failure in the United States (2001–2003): rationale, design and preliminary observations from the Acute Decompensated Heart Failure National Registry (ADHERE®). Am Heart J 2005;149:209–216.
  8. Muller JE, Turi ZG, Stone PH, et al: Digoxin therapy and mortality after myocardial infarction: experience in the MILIS study. N Engl J Med 1986;314:265–271.
  9. Berk RA, Newton PJ: Does arrest really deter wife battery? An effort to replicate findings of the Minneapolis Spouse Abuse Experiment. Am Sociol Rev 1985;50:253–262.
  10. Frigoletto FD, Lieberman E, Lang JM, et al: A clinical trial of active management of labor. N Engl J Med 1995;333:745–750.
  11. Furnival G, Wilson R: Regression by leaps and bounds. Technometrics 1974;16:499–511.

    External Resources

  12. Abraham WT, Adams KF, Fonarow GC, et al: In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure Registry (ADHERE®). J Am Coll Cardiol 2005;46:57–64.
  13. Nieminen MS, Bohm M, Cowie MR, et al: Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:384–416.
  14. DiDomenico RJ, Park HY, Southworth MR, et al: Guidelines for acute decompensated heart failure treatment. Ann Pharmacother 2004;38:649–660.
  15. McCurley JM, Hanlon SU, Wei SK, et al: Furosemide and the progression of left ventricular dysfunction in experimental heart failure. J Am Coll Cardiol 2004;44:1301–1307.
  16. Francis GS, Siegel RM, Goldsmith SR, et al: Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure: activation of the neurohumoral axis. Ann Intern Med 1985;103:1–6.
  17. Francis GS, Benedict C, Johnstone DE, et al: Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990;82:1724–1729.
  18. Kubo SH, Clark M, Laragh JH, et al: Identification of normal neurohormonal activity in mild congestive heart failure and stimulating effect of upright posture and diuretics. Am J Cardiol 1987;60:1322–1328.
  19. Cotter G, Weissgarten J, Metzkor E, et al: Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure. Clin Pharmacol Ther 1997;62:187–193.
  20. Gottlieb SS, Brater DC, Thomas I, et al: BG9719 (CVT-124), an A1 adenosine receptor antagonist protects against the decline in renal function observed with diuretics therapy. Circulation 2002;105:1348–1353.
  21. Smith GL, Vaccarino V, Kosiborod M, et al: Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure? J Card Fail 2003;9:13–25.
  22. Gottlieb SS, Abraham W, Butler J, et al: The prognostic importance of different definition of worsening renal function in congestive heart failure. J Card Fail 2002;8:136–141.
  23. Krumholz HM, Chen YT, Vaccarino V, et al: Correlates and impact on outcomes of worsening renal function in patients > or = 65 years of age with heart failure. Am J Cardiol 2000;85:1110–1113.
  24. Juurlink DN, Mamdani MM, Lee DS, et al: Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004;351:543–551.
  25. Weber KT: Furosemide in the long-term management of heart failure: the good, the bad, and the uncertain. J Am Coll Cardiol 2004;44:1308–1310.
  26. Ahokas RA, Warrington KJ, Gerling IC, et al: Aldosteronism and peripheral blood mononuclear cell activation: a neuroendocrine-immune interface. Circ Res 2003;93:e124–e135.
  27. Neuberg GW, Miller AB, O’Connor CM, et al: Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 2002;144:31–38.
  28. Mehta RL, Pascual MT, Soroko S, et al: Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA 2002;288:2547–2553.
  29. Krämer BK, Schweda F, Riegger GA: Diuretic treatment and diuretic resistance in heart failure. Am J Med 1999;106:90–96.
  30. De Bruyne LK: Mechanisms and management of diuretic resistance in congestive heart failure. Postgrad Med J 2003;79:268–271.
  31. Cotter G, Metzkor E, Kaluski E, et al: Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet 1998;351:389–393.
  32. Peacock WF, Fonarow GC, Emerman CL, et al: Impact of early initiation of intravenous therapy for acute decompensated heart failure on outcomes in ADHERE. Cardiology 2007;107:44–51.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50